N. Pérez-Diaz-Del-Campo, G. P. Caviglia, Giorgia La Piana, Marta Vernero, V. Schillaci, A. Armandi, F. Stalla, Demis Pitoni, E. Bugianesi, A. Ciancio, P. Cavalla, D. Ribaldone
{"title":"炎症性肠病患者多发性硬化的患病率","authors":"N. Pérez-Diaz-Del-Campo, G. P. Caviglia, Giorgia La Piana, Marta Vernero, V. Schillaci, A. Armandi, F. Stalla, Demis Pitoni, E. Bugianesi, A. Ciancio, P. Cavalla, D. Ribaldone","doi":"10.3390/gidisord5030023","DOIUrl":null,"url":null,"abstract":"Being two immune-mediated diseases (IMIDs), the association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) is plausible, but data in the literature are conflicting. The aim of our study was to evaluate the possible association between IBD and MS in a cohort of patients with IBD. In a retrospective study, we examined the medical records of 5739 patients with a confirmed diagnosis of IBD followed in our clinic between 1978 and 2022. Among these patients, we identified 14 with MS, with a prevalence of 0.24%. The reported prevalence of MS in the general population in Northern Italy in 2021 was 0.18% (p = 0.24). For each of the patients with MS identified, more than ten patients without MS were analyzed. The 14 MS cases were then compared with 342 controls. From the 14 patients with MS, 12 (85.7%) were female and 2 (14.3%) were male, while in the control group, 158 (46.2%) were female and 184 (53.8%) were male (p = 0.004). As for therapy, significant differences were found in mesalazine (5 (41.7%) cases vs. 317 (92.7%) controls, p < 0.0001) and anti-TNF treatment (0% cases vs. 26.6% controls, p = 0.03, respectively) at the time of MS diagnosis. Moreover, a Kaplan–Meier curve analysis showed that the 20-year survival probability was 98.4% for patients with IBD, while for patients diagnosed with MS and IBD it was 82.1% (p = 0.02). In conclusion, patients with IBD have a similar risk of developing MS compared to the general population, but female sex appears to increase the risk. Indeed, life expectancy at 20 years for patients with IBD and MS is lower than for patients with IBD alone.","PeriodicalId":73131,"journal":{"name":"Gastrointestinal disorders (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of Multiple Sclerosis in Patients with Inflammatory Bowel Disease\",\"authors\":\"N. Pérez-Diaz-Del-Campo, G. P. Caviglia, Giorgia La Piana, Marta Vernero, V. Schillaci, A. Armandi, F. Stalla, Demis Pitoni, E. Bugianesi, A. Ciancio, P. Cavalla, D. Ribaldone\",\"doi\":\"10.3390/gidisord5030023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Being two immune-mediated diseases (IMIDs), the association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) is plausible, but data in the literature are conflicting. The aim of our study was to evaluate the possible association between IBD and MS in a cohort of patients with IBD. In a retrospective study, we examined the medical records of 5739 patients with a confirmed diagnosis of IBD followed in our clinic between 1978 and 2022. Among these patients, we identified 14 with MS, with a prevalence of 0.24%. The reported prevalence of MS in the general population in Northern Italy in 2021 was 0.18% (p = 0.24). For each of the patients with MS identified, more than ten patients without MS were analyzed. The 14 MS cases were then compared with 342 controls. From the 14 patients with MS, 12 (85.7%) were female and 2 (14.3%) were male, while in the control group, 158 (46.2%) were female and 184 (53.8%) were male (p = 0.004). As for therapy, significant differences were found in mesalazine (5 (41.7%) cases vs. 317 (92.7%) controls, p < 0.0001) and anti-TNF treatment (0% cases vs. 26.6% controls, p = 0.03, respectively) at the time of MS diagnosis. Moreover, a Kaplan–Meier curve analysis showed that the 20-year survival probability was 98.4% for patients with IBD, while for patients diagnosed with MS and IBD it was 82.1% (p = 0.02). In conclusion, patients with IBD have a similar risk of developing MS compared to the general population, but female sex appears to increase the risk. Indeed, life expectancy at 20 years for patients with IBD and MS is lower than for patients with IBD alone.\",\"PeriodicalId\":73131,\"journal\":{\"name\":\"Gastrointestinal disorders (Basel, Switzerland)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastrointestinal disorders (Basel, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/gidisord5030023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastrointestinal disorders (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/gidisord5030023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
作为两种免疫介导的疾病(IMIDs),多发性硬化症(MS)和炎症性肠病(IBD)之间的联系似乎是合理的,但文献中的数据是相互矛盾的。本研究的目的是在一组IBD患者中评估IBD与MS之间可能的关联。在一项回顾性研究中,我们检查了1978年至2022年间在我们诊所确诊为IBD的5739例患者的医疗记录。在这些患者中,我们确定了14例MS,患病率为0.24%。据报道,2021年意大利北部普通人群中多发性硬化症的患病率为0.18% (p = 0.24)。对于每一个确定的多发性硬化症患者,分析了10多个非多发性硬化症患者。将14例MS病例与342例对照进行比较。14例MS患者中,女性12例(85.7%),男性2例(14.3%),对照组女性158例(46.2%),男性184例(53.8%)(p = 0.004)。治疗方面,MS诊断时美萨拉嗪组(5例(41.7%)vs对照组317例(92.7%),p < 0.0001)和抗tnf治疗组(0% vs 26.6%, p = 0.03)差异有统计学意义。Kaplan-Meier曲线分析显示,IBD患者20年生存率为98.4%,MS合并IBD患者20年生存率为82.1% (p = 0.02)。总之,与一般人群相比,IBD患者发生MS的风险相似,但女性似乎增加了风险。的确,IBD合并MS患者的预期寿命为20岁,低于单纯IBD患者。
Prevalence of Multiple Sclerosis in Patients with Inflammatory Bowel Disease
Being two immune-mediated diseases (IMIDs), the association between multiple sclerosis (MS) and inflammatory bowel disease (IBD) is plausible, but data in the literature are conflicting. The aim of our study was to evaluate the possible association between IBD and MS in a cohort of patients with IBD. In a retrospective study, we examined the medical records of 5739 patients with a confirmed diagnosis of IBD followed in our clinic between 1978 and 2022. Among these patients, we identified 14 with MS, with a prevalence of 0.24%. The reported prevalence of MS in the general population in Northern Italy in 2021 was 0.18% (p = 0.24). For each of the patients with MS identified, more than ten patients without MS were analyzed. The 14 MS cases were then compared with 342 controls. From the 14 patients with MS, 12 (85.7%) were female and 2 (14.3%) were male, while in the control group, 158 (46.2%) were female and 184 (53.8%) were male (p = 0.004). As for therapy, significant differences were found in mesalazine (5 (41.7%) cases vs. 317 (92.7%) controls, p < 0.0001) and anti-TNF treatment (0% cases vs. 26.6% controls, p = 0.03, respectively) at the time of MS diagnosis. Moreover, a Kaplan–Meier curve analysis showed that the 20-year survival probability was 98.4% for patients with IBD, while for patients diagnosed with MS and IBD it was 82.1% (p = 0.02). In conclusion, patients with IBD have a similar risk of developing MS compared to the general population, but female sex appears to increase the risk. Indeed, life expectancy at 20 years for patients with IBD and MS is lower than for patients with IBD alone.